Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have received an average rating of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $13.60.

Several equities analysts recently issued reports on OBIO shares. Wall Street Zen downgraded Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Barclays boosted their price target on Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. B. Riley Financial reduced their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday.

Orchestra BioMed Trading Down 0.5%

Shares of Orchestra BioMed stock opened at $3.69 on Wednesday. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The firm has a market capitalization of $220.96 million, a price-to-earnings ratio of -3.80 and a beta of 0.49. The firm’s 50 day simple moving average is $3.98 and its two-hundred day simple moving average is $4.14.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.07. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. Analysts predict that Orchestra BioMed will post -1.47 EPS for the current year.

Insider Buying and Selling

In other Orchestra BioMed news, Director Jason Aryeh acquired 8,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $3.90 per share, for a total transaction of $34,986.90. Following the purchase, the director owned 117,453 shares in the company, valued at approximately $458,066.70. The trade was a 8.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric S. Fain acquired 20,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $82,600.00. Following the completion of the acquisition, the director directly owned 91,709 shares in the company, valued at approximately $378,758.17. The trade was a 27.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 39,636 shares of company stock worth $158,081. 7.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Orchestra BioMed in the fourth quarter worth about $38,000. Virtu Financial LLC purchased a new position in Orchestra BioMed during the fourth quarter valued at approximately $57,000. Creative Planning acquired a new position in Orchestra BioMed in the second quarter valued at approximately $40,000. XTX Topco Ltd acquired a new position in Orchestra BioMed in the second quarter valued at approximately $45,000. Finally, Balyasny Asset Management L.P. purchased a new stake in Orchestra BioMed in the 4th quarter worth approximately $76,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.